Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hematologic Neoplasms 1HIV Infections 1

Interventions

Cyclophosphamide 15fludarabine 12Mycophenolic Acid 10Standard of Care 9Whole-Body Irradiation 7Tacrolimus 7venetoclax 6Specimen Handling 6Sirolimus 6Practice Guidelines as Topic 6trametinib 5Melphalan 5fludarabine phosphate 4Mesna 4Magnetic Resonance Spectroscopy 4Filgrastim 4Biopsy 4Behavior Therapy 4Azacitidine 4Thiotepa 3Peripheral Blood Stem Cell Transplantation 3GSK2636771 3Educational Status 3Crizotinib 3Busulfan 3thymoglobulin 2talquetamab 2ruxolitinib 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × axicabtagene ciloleucel × 90 days × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡